Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.76 USD
-0.19 (-0.83%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $22.60 -0.16 (-0.70%) 7:36 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 261 - 280 ( 286 total )
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Transparency on IND Timing for ATTR, Gene Editing Progress in Other Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
YE17 Financials; IND-Enabling Studies to Begin for Lead ATTR Candidate Mid-2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
ASH Presentations Highlight Gene Editing Progress in Hemoglobinopathies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Landmark Achieved with First Crispr/Cas9 Editing in Non- Human Primate Livers
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Updated Mouse Data Shows Long-Term Benefit with Crispr/ Cas9
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
ASGCT Presentations Show TTR Editing Success in Second Animal Model, We Expect Studies in Non-Human Primates to Start Later this Year, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Recent Presentations Highlight Gene Editing Success in Mouse Models, Studies in Non-Human Primates to Begin Later this Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
4Q/FY16, We Look for Additional Tech Improvements and Preclinical Progress in 2017, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Patent Interference Ruling Surprising, Expecting Appeals Ahead, Reiterate OP but Cutting PT to $25 on IP Overhang
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D